Inari Medical, Inc. (NARI)
After hours:
Chart Events
Performance Outlook
| Previous Close | 59.62 |
| Open | 61.39 |
| Bid | 58.10 x 1000 |
| Ask | 58.00 x 800 |
| Day's Range | 55.33 - 61.39 |
| 52 Week Range | 50.50 - 100.00 |
| Volume | |
| Avg. Volume | 827,706 |
| Market Cap | 3.093B |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.01 |
| Earnings Date | Aug 08, 2022 - Aug 12, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 111.67 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for NARI
Related Research
- Inari Medical, Inc.NARI: Raising target price to $65.00INARI MEDICAL INC has an Investment Rating of HOLD; a target price of $65.000000; an Industry Subrating of High; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Medium.RatingFair ValueEconomic Moat3 days agoArgus Research
- GlobeNewswire
Inari Medical Announces Launch of 2021 Ethos and Sustainability Report
IRVINE, Calif., May 13, 2022 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, announced the publication of its first ever “Ethos and Sustainability Report.” The report highlights Inari’s commitment to its ethos, and as part of that to environmental, social and governance (ESG) leadership. The report can be found on Inari’s website here. “I am proud to is
- Zacks
Inari Medical (NARI) Down 16.9% Despite Q1 Earnings Beat
Inari Medical's (NARI) first-quarter results benefit from significant progress made across all of its growth drivers.
- Benzinga
Inari Medical Q1 Earnings Beat Street View, Lifts FY22 Sales Outlook Above Consensus
View more earnings on NARISee more from BenzingaQuidel Clocks More Than Three-Fold Jump In COVID-19 ProductsPacific Biosciences Clocks 14% Jump In Q1 RevenuesDon't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
